Fiche société
Nuravax, Inc.
Traitements, essais et publications liés.
Traitements3programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| DUVAX 200 µgThis Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins. | Alzheimer | Phase 1 | United States | À vérifier | |
| DUVAX 400 µgThis Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins. | Alzheimer | Phase 1 | United States | À vérifier | |
| DUVAX 200 µgThis Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins. | Alzheimer | Phase 1 | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| DUVAX 200 µg | Alzheimer | Phase 1 | NCT07142278 | DU-PRISM — DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||